BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND LCK, YT16, 3932, P06239, ENSG00000182866, p56lck, pp58lck
156 results:

  • 1. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
    Gambino S; Quaglia FM; Galasso M; Cavallini C; Chignola R; Lovato O; Giacobazzi L; Caligola S; Adamo A; Putta S; Aparo A; Ferrarini I; Ugel S; Giugno R; Donadelli M; Dando I; Krampera M; Visco C; Scupoli MT
    Sci Rep; 2024 Mar; 14(1):6595. PubMed ID: 38503806
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Design, synthesis, and pharmacological evaluation of novel benzothiazole derivatives targeting lck in acute lymphoblastic leukemia.
    Chen Y; Zhang K; Tan J; Fan Z; Fu Y; Li X; Liu B; Wang G
    Bioorg Chem; 2024 Mar; 144():107180. PubMed ID: 38335758
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. CD27/CD70 pathway activation in primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.
    Richter J; Oschlies I; Kock K; Wüseke T; Haag J; Koch K; Klapper W
    J Pathol; 2024 Feb; 262(2):189-197. PubMed ID: 37933684
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
    Saygin C; Giordano G; Shimamoto K; Eisfelder B; Thomas-Toth A; Venkataraman G; Ananthanarayanan V; Vincent TL; DuVall A; Patel AA; Chen Y; Tan F; Anthony SP; Chen Y; Shen Y; Odenike O; Teachey DT; Kee BL; LaBelle J; Stock W
    Clin Cancer Res; 2023 Aug; 29(16):3151-3161. PubMed ID: 37363966
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
    Yoshimura S; Panetta JC; Hu J; Li L; Gocho Y; Du G; Umezawa A; Karol SE; Pui CH; Mullighan CG; Konopleva M; Stock W; Teachey DT; Jain N; Yang JJ
    Leukemia; 2023 Jun; 37(6):1194-1203. PubMed ID: 37076694
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. ArtinM Cytotoxicity in B Cells Derived from Non-Hodgkin's lymphoma Depends on Syk and Src Family Kinases.
    Barboza BR; Thomaz SMO; Junior AC; Espreafico EM; Miyamoto JG; Tashima AK; Camacho MF; Zelanis A; Roque-Barreira MC; da Silva TA
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674590
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia.
    Jin Q; Gutierrez Diaz B; Pieters T; Zhou Y; Narang S; Fijalkwoski I; Borin C; Van Laere J; Payton M; Cho BK; Han C; Sun L; Serafin V; Yacu G; Von Loocke W; Basso G; Veltri G; Dreveny I; Ben-Sahra I; Goo YA; Safgren SL; Tsai YC; Bornhauser B; Suraneni PK; Gaspar-Maia A; Kandela I; Van Vlierberghe P; Crispino JD; Tsirigos A; Ntziachristos P
    Sci Adv; 2022 Dec; 8(49):eabq8437. PubMed ID: 36490346
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Preclinical evaluation of proteolytic targeting of lck as a therapeutic approach in T cell acute lymphoblastic leukemia.
    Hu J; Jarusiewicz J; Du G; Nishiguchi G; Yoshimura S; Panetta JC; Li Z; Min J; Yang L; Chepyala D; Actis M; Reyes N; Smart B; Pui CH; Teachey DT; Rankovic Z; Yang JJ
    Sci Transl Med; 2022 Aug; 14(659):eabo5228. PubMed ID: 36001679
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120.
    Fazio G; Bresolin S; Silvestri D; Quadri M; Saitta C; Vendramini E; Buldini B; Palmi C; Bardini M; Grioni A; Rigamonti S; Galbiati M; Mecca S; Savino AM; Peloso A; Tu JW; Bhatia S; Borkhardt A; Micalizzi C; Lo Nigro L; Locatelli F; Conter V; Rizzari C; Valsecchi MG; Te Kronnie G; Biondi A; Cazzaniga G
    EBioMedicine; 2022 Sep; 83():104224. PubMed ID: 35985167
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Phospho-Specific Flow Cytometry Reveals Signaling Heterogeneity in T-Cell Acute Lymphoblastic Leukemia Cell Lines.
    Perbellini O; Cavallini C; Chignola R; Galasso M; Scupoli MT
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805156
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro.
    Kauer J; Märklin M; Pflügler M; Hörner S; Hinterleitner C; Tandler C; Jung G; Salih HR; Heitmann JS
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2759-2771. PubMed ID: 35551463
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Therapeutic targeting of lck tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
    Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
    Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Dasatinib-therapy induced sustained remission in a child with refractory TCF7-SPI1 T-cell acute lymphoblastic leukemia.
    He Y; Zhang J; Zhang Y; Hu Z; Wang P; Gan W; Xie S; Qian M; Pui CH; Jiang H; Zhu X; Zhang H; Zhang W
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29724. PubMed ID: 35441457
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The interactions of CAP and LYN with the insulin signaling transducer CBL play an important role in polycystic ovary syndrome.
    Shen H; Xu X; Fu Z; Xu C; Wang Y
    Metabolism; 2022 Jun; 131():155164. PubMed ID: 35217034
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Adiponectin and Its Effects on Acute Leukemia Cells: An Experimental and Bioinformatics Approach.
    Tsartsalis AN; Tagka A; Kotoulas A; Mirkopoulou D; Geronikolou SA; G L
    Adv Exp Med Biol; 2021; 1338():117-127. PubMed ID: 34973016
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.
    Zhang H; Hu Y; Shao M; Teng X; Jiang P; Wang X; Wang H; Cui J; Yu J; Liang Z; Ding L; Han Y; Wei J; Xu Y; Li X; Shan W; Shi J; Luo Y; Qian P; Huang H
    J Hematol Oncol; 2021 Jul; 14(1):113. PubMed ID: 34289897
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Network-based systems pharmacology reveals heterogeneity in lck and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
    Gocho Y; Liu J; Hu J; Yang W; Dharia NV; Zhang J; Shi H; Du G; John A; Lin TN; Hunt J; Huang X; Ju B; Rowland L; Shi L; Maxwell D; Smart B; Crews KR; Yang W; Hagiwara K; Zhang Y; Roberts K; Wang H; Jabbour E; Stock W; Eisfelder B; Paietta E; Newman S; Roti G; Litzow M; Easton J; Zhang J; Peng J; Chi H; Pounds S; Relling MV; Inaba H; Zhu X; Kornblau S; Pui CH; Konopleva M; Teachey D; Mullighan CG; Stegmaier K; Evans WE; Yu J; Yang JJ
    Nat Cancer; 2021 Mar; 2(3):284-299. PubMed ID: 34151288
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-lck hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified.
    Debackere K; Marcelis L; Demeyer S; Vanden Bempt M; Mentens N; Gielen O; Jacobs K; Broux M; Verhoef G; Michaux L; Graux C; Wlodarska I; Gaulard P; de Leval L; Tousseyn T; Cools J; Dierickx D
    Nat Commun; 2021 Jun; 12(1):3705. PubMed ID: 34140493
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Novel Targeted Photosensitizer as an Immunomodulator for Highly Efficient Therapy of T-Cell Acute Lymphoblastic Leukemia.
    Yuan G; Yao M; Lv H; Jia X; Chen J; Xue J
    J Med Chem; 2020 Dec; 63(24):15655-15667. PubMed ID: 33300796
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Wnt signaling mediates oncogenic synergy between Akt and Dlx5 in T-cell lymphomagenesis by enhancing cholesterol synthesis.
    Tan Y; Sementino E; Liu Z; Cai KQ; Testa JR
    Sci Rep; 2020 Sep; 10(1):15837. PubMed ID: 32985581
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 8.